GlassScriptPhysician profile
Austin R Burnett
NPI 1225346380
$8,615.42
in general payments reported to CMS, 2019-2025
59 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,010 · 2022: $1,846 · 2023: $1,854 · 2024: $1,714 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,760.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,380.83 | 2021-2025 | |
| Novo Nordisk INC | $832.23 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $594.67 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $424.79 | 2021-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $396.92 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $340.91 | 2021-2025 | Freestyle Libre |
| Esperion Therapeutics, INC. | $309.75 | 2021-2024 | Nexletol |
| Pfizer INC. | $263.96 | 2021-2025 | |
| Kaleo, INC. | $263.82 | 2021-2023 | Auvi-Q |
| Lundbeck LLC | $249.06 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $242.13 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $223.91 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $221.77 | 2021-2024 | Onzetra Xsail, Contrave |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.78 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $166.21 | 2021-2024 | Trintellix |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.